Publications

1. Molecular evolution of the HIV-1 integrase at the population level in Germany between 1986-2006 prior to the approval of integrase inhibitors
   K. Meixenberger, K. P. Yousef, S. Somogyi, S. Fiedler, B. Bartmeyer, Max von Kleist, C. Kücherer
   submitted, 2014

2. Mutational Interference Mapping Experiment (MIME) for studying the relationship between RNA structure and function
   R.P. Smyth, L. Despons, G. Huili, S. Bernacchi, M. Hijnen, J. Mak, F. Jossinet, L. Weixi, J-C. Paillart, Max von Kleist, R. Marquet
   submitted, 2014

3. Optimal treatment strategies in the context of 'treatment for prevention' against HIV/1 in resource-poor settings
   S. Duwal, S. Winkelmann, C. Schütte and Max von Kleist
   submitted, 2014

4. Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker to indentify recent infections in HIV-1 incidence studies
   K. Meixenberger, A. Hauser, K. Jansen, K. P. Yousef, S. Fiedler, Max von Kleist, S. Norley, S.Somogyi, O. Hamouda, N. Bannert, B. Bartmeyer, C. Kücherer
   Journal of Clinical Microbiology 52, 2977-83, 2014 ( online )

5. Awareness and Utilization of Standards and Pathways for the Reporting of Adverse Events Following Immunization among Pediatricians in Russia and Germany
   S. Muehlhans, Max von Kleist T. Gretchukha, T. Martin, U. Fegeler, W. Maurer, L. Namazova-Baranova, G. Gaedicke, A. Baranov, B. Rath
   Pediatric Drugs 16, 321-30, 2014 ( online )

6. "Time-to-Amphotericin B" in Cryptococcal Meningitis in a European Low-Prevalence Setting: Analysis of Diagnostic Delays
   J. Katchanov, Max von Kleist, K. Arasteh, H. Stocker
   QJM: An International Journal of Medicine 107, 799, 2014 ( online )

7. Quantitative influenza follow-up testing (QIFT) - a novel biomarker for the monitoring of disease activity at the point-of-care
   X. Chen, K. P. Yousef, S. Duwe, K. Karsch, S. Grover, S. Wählisch, P. Obermeier, F. Tief, S. Muehlhans, L. Seeber, Max von Kleist, B. Schweiger, B. Rath
   Plos One 9, e92500, 2014 ( open access )

8. Markov Control Processes with Rare State Observation: Theory and Application to Treatment Scheduling in HIV-1
   S. Winkelmann, C. Schütte and Max von Kleist
   Communications in Mathematical Sciences 12, 859, 2014 ( online )

9. "Markov Control with Rare State Observation": Sensitivity Analysis with Respect to Optimal Treatment Strategies against HIV-1
   S. Winkelmann, C. Schütte and Max von Kleist
   International Journal of Biomathematics and Biostatistics 2, 1, 2013 ( pdf of preprint )

10. Towards a personalized approach to managing of influenza infections in infants and children - food for thought and a note on oseltamivir
    B. Rath, F. Tief, K. Karsch, S. Muehlhans, P. Obermeier, E. Adamou, X. Chen, L. Seeber, C. Peiser, C. Hoppe, M. von Kleist, T. Conrad, B. Schweiger
    Infectious Disorders - Drug Targets 13 , 25, 2013 ( online )

11. In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis
    B. Rath, K. P. Yousef, D. K. Katzenstein, R. W. Shafer, Ch. Schütte, M. von Kleist and T. C. Merigan
    PLoS One 8 , e61102, 2013 ( open access )

12. Antiviral Resistance and Predictors of Virologic Failure in the first Cohort of HIV-infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis
    B. Rath, M. von Kleist, M. E. Castillo, L. Kolevic, P. Caballero, G. Soto-Castellares, A. M. Amedee, J. E. Robinson, D. K. Katzenstein, R. B. Van Dyke and R. Oberhelman
    BMC Infect Dis 13, 1, 2013 ( open access )

13. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenefovir and Prophylactic Efficacy against HIV-1 Infection
    S. Duwal, C. Schütte and M. von Kleist
    PLoS One 8, e40382, 2012 ( open access )

14. Virus Load Kinetics and Resistance Development during Oseltamivir Treatment in Infants and Children Infected with Influenza A (H1N1) 2009 and Influenza B Viruses
    B. Rath, M. von Kleist, F. Tief, K. Karsch, E. Türk, S. Mühlhans, F. Louis, H. Skopnik, B. Schweiger and S. Duwe
    Pediatr Infect Dis J. 31, 9, 2012( online )

15. HIV-1 polymerase inhibition by nucleoside analogs: Cellular- and kinetic parameters of efficacy, susceptibility and resistance selection
    M. von Kleist, P. Metzner, R. Marquet and C. Schütte
    PLoS Comput. Biol.8, e1002359, 2012 ( open access )

16. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: A combined pharmacokinetic, pharmaco- and viral dynamic analysis to predict clinical outcomes.
    M. Frank*, M. von Kleist*, A. Kunz, G. Harms, C. Schütte and C. Kloft.
    Antimicrob. Agents Chemother 55, 5529, 2011 ( open access )
    *equally contributed

17. Reduction technique for pharmacological models to support planning, execution and analysis of clinical studies (patent).
    M. von Kleist (67%) and Christof Schutte (33%) .
    German patent office. Pat.Nr.: 10 2010 060 311, 2010 ( link )

18. HIV quasi-species dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.
    M. von Kleist, S. Menz, H. Stocker, K. Arasteh, C. Schütte and W. Huisinga
    PLoS ONE 6, e18204, 2011 ( open access )

19. A Drug-Class specific impact of antivirals on the reproductive capacity of HIV
    M. von Kleist, Stephan Menz and W. Huisinga
    PLoS Comput. Biol. 6, e1000720, 2010 ( open access )

20. Pharmacokinetic-Pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on Zidovudine
    M. von Kleist and W. Huisinga
    Eur J Pharm Sci 36, 532, 2009 ( online )

21. Combining Systems Biology with physiologically-based pharmacokinetics to support the understanding of drug effects
    M. von Kleist, C. Kloft and W. Huisinga
    Proceedings of Foundations of Systems Biology in Engeneering FOSBE, 231, 2007 (pdf of preprint )

22. Physiologically based pharmacokinetic modelling: A sub-compartmentalized model of tissue distribution
    M. von Kleist and W. Huisinga
    J. Pharmakokinet. Pharmacodyn. 34, 789, 2007 ( online )

23. Software Supported Modelling in Pharmacokinetics
    R. Telgmann, M. von Kleist, and W. Huisinga
    LNCS 4216, 216, 2006 ( online )

24. Update on Antiviral DNA Vaccine Research (2000-2003)
    D. Franke, J. Pavlovic, T. S. Utesch, M. von Kleist, J. Schultz, G. Dollenmaier and K. Moelling.
    in Novel Vaccination Strategies Stefan H. E. Kaufmann (ed.), Wiley 2004 (online)